The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
|Webcasts|April 1, 2020
Oral Peptide Delivery Utilizing Specialized Encapsulation Technologies
Author(s)Lonza Pharma & Biotech
This webcast will cover physicochemical requirements and biological oral delivery barriers for peptides. Learn innovative approaches to derisk pharmaceutical development and increase the success rate of the first in human trials. Live: Wednesday, Apr. 1, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Apr. 1, 2021 Register free
Register free:
Event Overview:
Technological enhancements in peptide discovery and synthesis are emerging to meet the increasing number of incidences of cardiovascular and metabolic diseases. However, targeted delivery of peptide drugs within the therapeutic range remains a significant challenge for the biopharmaceutical industry. Parenteral administration-including intravenous, subcutaneous, and intramuscular injection-remains the primary method for commercialized therapeutic peptides.
From a patient perspective, oral administration is a preferred drug delivery method, providing improved patient compliance and facilitating outpatient therapy for chronic indications. Non-invasive delivery methods such as oral administration have increased over the past five years through the innovation efforts at start-up and big pharma companies. Indeed, the September 2019 approval of Rybelsus, (semaglutide) from Novo Nordisk is seen as a game changer within the industry as it allows oral delivery of high molecular weight (>1300 MW) peptide delivery.
This webcast will cover the physicochemical requirements for peptides and biological oral delivery barriers. Both aspects are crucial to de-risk pharmaceutical development and increase the success rate of first-in-human trials using innovative approaches.
Key Learning Objectives:
- Understand physicochemical attributes of peptide for oral routes administration
- Review performance criteria for peptide formulation
- Learn about biological hurdles to overcome low oral bioavailability of formulated peptides
Speaker: Dr. Hassan Benameur, Chief Scientific Officer Chemical Division, Lonza Pharma & Biotech
Time and date: Wednesday, Apr. 1, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after airing until Apr. 1, 2021
Sponsor: Lonza Pharma & Biotech
Register free:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.